{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:55:25Z","timestamp":1791381325939,"version":"4.3.3"},"reference-count":66,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer is one of the leading causes of death globally. Owing to high toxicity, patients using chemotherapy drugs have a higher risk for developing adverse drug reactions (ADRs). Pharmacovigilance studies are essential in oncology to evaluate ADRs caused by anticancer drugs and improve patient safety. This study aimed to analyze serious ADRs associated with the use of doxorubicin and epirubicin reported to VigiBase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>All anonymized data on suspected ADRs for doxorubicin and epirubicin as \u2018serious\u2019 and \u2018suspected\u2019 or \u2018interacting\u2019 drugs between 1968 and 30 August 2021, were extracted from VigiBase. Descriptive statistics were conducted in Microsoft Excel, and data were summarized using frequencies and percentages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 35,620 serious individual case safety reports was analyzed. The majority of reports were from females (Dox\u2009=\u200961.41%; Epi\u2009=\u200986.56%), while the predominant age group was 45\u201364 years (Dox\u2009=\u200942.06%; Epi\u2009=\u200957.39%). Physicians were the more likely group to report serious ADRs (Dox\u2009=\u200950.03%; Epi\u2009=\u200934.11%). In general, Europe reported the highest for doxorubicin (38.08%), while Asia recorded the highest reports for epirubicin (53.28%). Oceania reported the least for both drugs (Dox\u2009=\u20090.45%; Epi\u2009=\u20090.04%), followed by Africa (Dox\u2009=\u20090.72%; Epi\u2009=\u20090.29%). Blood and lymphatic system disorders were the most reported serious category (Dox\u2009=\u200911053 [44.47%]; Epi\u2009=\u20096659 [61.84%]). The most common manifestations were febrile neutropenia (Dox\u2009=\u200910.52%) and bone marrow failure (Epi\u2009=\u200923.89%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides relevant global insights into serious ADRs for doxorubicin and epirubicin. This knowledge may assist in minimizing and proactively managing ADRs. It can also inform policies to improve patients\u2019 quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221113578","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T02:14:33Z","timestamp":1657764873000},"page":"252-262","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from VigiBase"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9869-9926","authenticated-orcid":false,"given":"Deborah A.","family":"Matesun","sequence":"first","affiliation":[{"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7971-4270","authenticated-orcid":false,"given":"Kofi Boamah","family":"Mensah","sequence":"additional","affiliation":[{"name":"Kwame Nkrumah University of Science and Technology"},{"name":"College of Health Sciences, University of KwaZulu-Natal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Yamoah","sequence":"additional","affiliation":[{"name":"University of Health and Allied Sciences"},{"name":"College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Bangalee","sequence":"additional","affiliation":[{"name":"College of Health Sciences, University of KwaZulu-Natal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-8702","authenticated-orcid":false,"given":"Neelaveni","family":"Padayachee","sequence":"additional","affiliation":[{"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"World Health Organization. Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10 million cancer deaths in 2020. International agency for research on cancer. Geneva: World Health Organization https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer# (2020 accessed 12 November 2021)."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21199"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119738"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21442"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184360"},{"key":"e_1_3_2_7_2","first-page":"169","article-title":"A survey on correlative symptoms and its influence on quality of life in breast cancer patients","volume":"7","author":"Ma L","year":"2007","unstructured":"Ma L, Wang SP, Chung JO. A survey on correlative symptoms and its influence on quality of life in breast cancer patients. Chin J Evid Based Med2007; 7: 169\u2013174.","journal-title":"Chin J Evid Based Med"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.3824"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.56.2.6"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12233"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010432.pub2"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199345050-00011"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2003.s.012"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"e_1_3_2_15_2","unstructured":"Douedi S Carson MP. Anthracycline medications (Doxorubicin). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551633. (2021 accessed 30 December 2021)."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00463-0"},{"key":"e_1_3_2_17_2","unstructured":"World Health Organization. World Health Organization model list of essential medicines 22nd list Geneva: World Health Organization. (No. WHO\/MVP\/EMP\/IAU\/2019.07) https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2021.02 (2021 accessed 5 December 2021)."},{"key":"e_1_3_2_18_2","unstructured":"National Essential Medicines List Committee. http:\/\/www.kznhealth.gov.za\/pharmacy\/Tertiary-quaternary-level-essential-medicine-recommendations_January2020.pdf. (2020 accessed 12 November 2021)."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.008"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000483"},{"key":"e_1_3_2_21_2","unstructured":"Venkatesh P Kasi A. Anthracyclines. In:StatPearls. StatPearls Publishing Treasure Island (FL). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538187\/ (2019 accessed 10 November 2021)."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6711-0"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11407"},{"key":"e_1_3_2_24_2","unstructured":"World Health Organization. The importance of pharmacovigilance. Safety monitoring of medicinal products. World Health Organization. Geneva https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/42493\/a75646.pdf?sequence=1&isAllowed=y (2002 accessed 5 February 2022)."},{"key":"e_1_3_2_25_2","first-page":"90927","article-title":"Thalidomide and congenital abnormalities","volume":"2","author":"McBride WG","year":"1961","unstructured":"McBride WG. Thalidomide and congenital abnormalities. Lancet1961; 2: 90927\u20138.","journal-title":"Lancet"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01953.x"},{"key":"e_1_3_2_27_2","unstructured":"Uppsala Monitoring Centre (UMC). Members of the WHO Programme for International Drug Monitoring. 2021 https:\/\/www.who-umc.org\/global-pharmacovigilance\/who-programme-for-international-drug-monitoring\/who-programme-members\/ (2021 accessed 10 November 2021)."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_3_2_29_2","first-page":"20","article-title":"Spontaneous reporting in pharmacovigilance: strengths, weaknesses and recent methods of analysis","volume":"1","author":"Kasliwal R","year":"2012","unstructured":"Kasliwal R. Spontaneous reporting in pharmacovigilance: strengths, weaknesses and recent methods of analysis. J Clin Prev Cardiol2012; 1: 20\u201323.","journal-title":"J Clin Prev Cardiol"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098611425695"},{"key":"e_1_3_2_31_2","article-title":"Spontaneous reporting in the United States","author":"Kennedy DL","unstructured":"Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. In: Strom BL (ed) Pharmacoepidermiology. 3rd ed. Chichester: John Wiley and Sons, 2000, pp. 149\u2013174.","journal-title":"Pharmacoepidermiology"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.7613"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0706-9"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/009286150804200501"},{"key":"e_1_3_2_35_2","first-page":"386","article-title":"Prospective observational, non-randomized, parallel sequence study for assessment of adverse drug reactions due to chemotherapeutic treatment in different types of cancer patients","volume":"4","author":"Mrugank BP","year":"2013","unstructured":"Mrugank BP, Hareesha RP. Prospective observational, non-randomized, parallel sequence study for assessment of adverse drug reactions due to chemotherapeutic treatment in different types of cancer patients. Int J Pharm Sci Res2013; 4: 386.","journal-title":"Int J Pharm Sci Res"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102060-00001"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00817.x"},{"key":"e_1_3_2_38_2","unstructured":"United States. General Accounting Office. Drug safety: most drugs withdrawn in recent years had greater health risks for women. The Office; 2001."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00191158"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510210076031"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/187103"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2004.01.010"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/0960327113512860"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-016-0440-0"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2006.05.003"},{"key":"e_1_3_2_46_2","first-page":"1223","volume-title":"Melmon and Morrelli\u2019s Clinical Pharmacology: Basic Principles in Therapeutics","author":"Bates DW","year":"2000","unstructured":"Bates DW, Leape LL, Carruthers SG. Adverse drug reactions. In: Carruther SG, Hoffman BB, Melmon KL, Nierenberg DW (eds) Melmon and Morrelli\u2019s Clinical Pharmacology: Basic Principles in Therapeutics. 4th ed.New York: McGraw-Hill Medical Publishing Division, 2000, pp.1223.","edition":"4"},{"key":"e_1_3_2_47_2","unstructured":"United Nations Department of economic and social affairs population division. World population prospects 2019: highlights https:\/\/population.un.org\/wpp\/Download\/Standard\/Population\/ (2019 accessed 16 February 2022)."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta15200"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02746.x"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-10-780"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2020.04.007"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03262002"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9512-5"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.003"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03477.x"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20423"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70325-9"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1132-4"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000665"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2008.09.007"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1221401"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000156"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201304-097OC"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.240"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx365.058"},{"key":"e_1_3_2_66_2","unstructured":"World Health Organization. WHO Pharmaceutical Newsletters. World Health Organization. Geneva https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/330444\/WPN-2019-06-eng.pdf?ua=1 (2019 accessed 30 January 2022)."},{"key":"e_1_3_2_67_2","unstructured":"Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment http:\/\/who-umc.org\/Graphics\/24734.pdf (2018 accessed 9 February 2022)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221113578","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221113578","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221113578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:18Z","timestamp":1777688838000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221113578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/10781552221113578"],"URL":"https:\/\/doi.org\/10.1177\/10781552221113578","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]}}}